Search
for
Sort by
Research 61–90 of 790
- A phase 2a trial of brepocitinib for cicatricial alopecia
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
- Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
- Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Treatment of severe alopecia areata with baricitinib
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- Unexpected Extensive Hair Whitening Following Baricitinib Treatment for Alopecia Universalis: A Case Report and Mechanistic Insights
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- A review of Janus kinase inhibitor use in scarring alopecia
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review